Effects of fluoroquinolone antibiotics on extracellular matrix-related phenotypes in tendon cells Authors: Akshay Anand, Keiko Sakai, David Dickens, Sadatoshi Tsuzuki, Sachiko Minamiguchi, Naoya Asai, Ahmed Kazaili, Riaz Akhtar, Munir Pirmohamed, Takao Sakai Published: 2026 ABSTRACT Fluoroquinolones (FQ) are amongst the most widely prescribed antibiotics used to treat a wide range of infections because of their excellent gastrointestinal absorption, superior tissue penetration and broad-spectrum activity. However, FQs can cause rare, though serious, collagen-associated adverse reactions, including tendinopathy, and there is still no clear framework for understanding the phenotypes relating to how tenocyte-produced extracellular matrix (ECM) and related molecules change in response to FQs. Here, we show carrier-mediated intracellular uptake of the FQ ciprofloxacin by mouse tendon cells in vitro. FQ antibiotics downregulated not only the production of the main component of tendon ECM, type I collagen, but also its assembly capacity and hydroxyproline content, which was accompanied by reduced fibronectin production. Treatment of tendon cells with ciprofloxacin downregulated the enzymatic activity of lysyl oxidase and the stiffness and diameter of collagen fibrils in vitro. Furthermore, ciprofloxacin-treated tendon cells exhibited decreased expression of active β1-integrin, the key ECM receptor. Thus, the reduction in fibronectin production and active β1-integrin expression support the notion that anoikis could be the pathological basis for FQ-induced tendinopathy together with adverse phenotypes that involve type I collagen.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-55720-5. Introduction Fluoroquinolone (FQ) antibiotics are widely prescribed synthetic antibiotics that exert their antimicrobial effect by preventing energy-dependent negative supercoiling of bacterial DNA through inhibition of DNA gyrase. FQs are effective against a wide range of infections due to their excellent gastrointestinal absorption, superior tissue penetration and broad-spectrum activity1,2. However, FQs can cause rare, though serious, adverse reactions (ADRs) including tendinopathy and potentially life-threatening aortic dissection3,4. Recent observational studies have indicated that tendon rupture5, as well as aortic aneurysms and dissections6, are more common during FQ treatment than during control periods. FQs have previously been implicated in retinal detachment, but recent cohort studies have concluded that there is no clinically significant increase in the incidence of retinal detachment during FQ treatment5,7–9. More recently, FQs have been associated with fluoroquinolone-associated disability (FQAD), a multi-system adverse reaction with an unclear pathogenesis, which can be life-changing10. The clinical importance of FQ-associated ADRs, including FQAD, is being increasingly recognized, leading to warnings and restrictions on clinical use from UK, European and US regulatory authorities5. Although FQs in general have been implicated in ADRs, some FQs are more strongly implicated than others11. Analyzing the dynamic properties of FQ-mediated transporters is crucial for understanding the adverse effects of FQs12. Members of the Solute Carrier (SLC) family, such as organic anion transporting polypeptides (OATP, organic anion transporter [OAT] family), and ATP-binding cassette (ABC) transporters are known to mediate the cellular influx and efflux, respectively, of FQs13. Their inhibition can significantly affect the pharmacokinetic characteristics of the FQ ciprofloxacin; for example, both orange juice and probenecid alter ciprofloxacin plasma concentrations in humans via transporter-mediated inhibition14,15. However, to date, nothing is known about which transporters are responsible for FQ transport in tendon cells. Tendon is a dense fibrous connective tissue composed of residential tendon cells (termed “tenocytes”) and densely packed, hydroxyproline-rich collagens (60–85% dry mass) bound to non-collagenous extracellular matrix (ECM) components. Tendon has a hierarchical fibrillar arrangement whereby triple-helical type I collagen bundles assemble into fibrils16. Tendon transfers contraction forces (tensile loading) from skeletal muscles to bones, which enables joint movement and provides stability to the musculoskeletal system. Tendinopathy is associated with deterioration in collagen structure and disorganization of the ECM17,18. Tendon collagen is renowned for its stability with more than 95% never being turned over in healthy tendon19. The small fraction that is synthesized and removed on a daily basis is, however, implicated in protecting tendons from fatigue (reviewed in Ref.20), and it has recently been reported that abnormally high tendon collagen turnover over many years precedes tendinopathy21. It is known that the expression levels of ECMs such as type I collagen decrease in human tendon cells and human aortic smooth muscle cells in response to FQs22,23. However, to date, no detailed study has explored the functional links between FQ antibiotics and ECM-related phenotypes in adult tendon cells. Given the multiple factors involved in FQ-induced changes to collagen structure, there is a clear need for investigation and comparative observation. In the present study, we aimed to elucidate the FQ-induced phenotypic changes in collagen production, collagen structure and network organization, as well as the degree of stiffness of collagen fibrils, in adult mouse tendon cells. Results Mouse tendon cell viability in response to FQ antibiotics First, to investigate the potential of FQs to cause cytotoxicity towards adult mouse Achilles tendon cell lines, an MTS cell viability assay was performed. In the concentration range 1 µM to 1 mM, greater than 100% cell viability was observed in the presence of ciprofloxacin and greater than 90% in the presence of levofloxacin (Fig. 1), indicating that there was no apparent cytotoxicity to the tendon cell lines in this concentration range. A pharmacokinetic study of FQs in mouse models shows a maximal concentration of ciprofloxacin in tissue of ~ 120 µM24. Therefore, for further study we selected 100 µM as a non-cytotoxic concentration of ciprofloxacin and levofloxacin that is close to the physiological maximum.Fig. 1Cell response to FQs in adult mouse tendon cells. FQ dose–response curves for cell viability (MTS assay). Tendon cells were cultured with different concentrations of levofloxacin or ciprofloxacin for 24 h. Dose responses are shown relative to the control value of 100% (cultured with vehicle alone). Error bars represent the standard deviation (S.D.) (n = 3). Cell response to FQs in adult mouse tendon cells. FQ dose–response curves for cell viability (MTS assay). Tendon cells were cultured with different concentrations of levofloxacin or ciprofloxacin for 24 h. Dose responses are shown relative to the control value of 100% (cultured with vehicle alone). Error bars represent the standard deviation (S.D.) (n = 3). Uptake of FQ ciprofloxacin into mouse tendon cells The important unsolved question is whether a carrier-mediated intracellular uptake system for FQs exists in tendon cells. Since nothing is known about which transporters are responsible for FQ transport in tendon cells, time-course FQ uptake assays25 were carried out. [3H]-Ciprofloxacin uptake into adult mouse tendon cells exhibited carrier-mediated uptake kinetics with accumulation that levelled off at about 30 min (114.4 ± 1.25 pmol/million cells) (Fig. 2A). The presence of carrier-mediated transport was further confirmed by the temperature dependence of the uptake assay: that [3H]-Ciprofloxacin uptake was significantly (~ 6.4-fold) lower at 4 °C (8.2 ± 1.4 pmol/million cells) than at 37 °C (52.2 ± 2.4 pmol/million cells) (Fig. 2B).Fig. 2[3H]-Ciprofloxacin is actively transported into mouse tendon cells. (A) Time course of uptake (up to 60 min) and (B) effect of temperature on uptake (for 5 min) of 10 µM [3H]-ciprofloxacin. (C) Effect of flavonoid hesperidin on uptake of 10 µM [3H]-ciprofloxacin (for 5 min). Data are means ± S.D. (n = 3). *, p < 0.05; **, p < 0.01. Cont, untreated controls. [3H]-Ciprofloxacin is actively transported into mouse tendon cells. (A) Time course of uptake (up to 60 min) and (B) effect of temperature on uptake (for 5 min) of 10 µM [3H]-ciprofloxacin. (C) Effect of flavonoid hesperidin on uptake of 10 µM [3H]-ciprofloxacin (for 5 min). Data are means ± S.D. (n = 3). *, p < 0.05; **, p < 0.01. Cont, untreated controls. Based on the previous evidence showing that FQ transport is mediated by several transporters in various systems26,27, we focused on FQ uptake inhibition assays and chose several candidate influx-transporter inhibitors such as hesperidin, naringin, quercetin, and tetraethyl ammonium chloride (TEA). Hesperidin, which is present in orange juice and is an inhibitor of human OATP1A228, significantly inhibited [3H]-ciprofloxacin uptake in mouse tendon cells, but only by up to ~ 25.8% (Fig. 2C). The other influx transporter inhibitors tested (10–100 µM) had no significant effect (data not shown). Quantitative real-time PCR (qRT-PCR) analysis of OATP genes confirmed that only slco1a5 (OATP-1A5), one of the mouse homologues of human OATP1A229, was detectable in mouse tendon cells, and that no other slco genes, including slco22A6 and slco22A8 (mouse homologues of human organic anion transporter (OAT) family members OAT1 and OAT3, respectively)29 were detected (data not shown), suggesting that OATP1A5 (slco1a5) accounts for only a part of the observed FQ influx in mouse tendon cells. We confirmed that inhibitors used did not affect the viability of tendon cells at the concentrations used (data not shown). FQs alter ECM production and downregulate type I collagen assembly in vitro (Re-)organization of the collagen network is a critical process that occurs upon tissue damage and/or remodeling30,31. Therefore, we next analyzed the expression of type I collagen, and nucleation factors for collagen network organization, namely fibronectin and type V collagen32,33. Treatment of tendon cells with levofloxacin and ciprofloxacin (100 µM) resulted in a significant reduction of the expression of type I collagen mRNA (p < 0.01) and protein (~ 29% with levofloxacin and ~ 47% with ciprofloxacin) as well as fibronectin mRNA (p < 0.01) and protein (~ 22% with levofloxacin and ~ 34% with ciprofloxacin). In contrast, type V collagen mRNA and protein levels were significantly increased, with protein expression increasing by ~ 210% with levofloxacin and ~ 242% with ciprofloxacin (Fig. 3).Fig. 3Treatment of mouse tendon cells with 100 µM levofloxacin or ciprofloxacin for 48 h results in reduced type I collagen and fibronectin and increased type V collagen protein and mRNA levels. (A–C) Type I collagen (A), fibronectin (B), and type V collagen (C) protein expression. β actin was used as the loading control. The band intensities were measured by densitometry and normalized to each β actin (loading control) intensity, and the intensity of the control sample band (untreated cells) was set to 1. Each value is shown relative to this control value. Data are means ± S.D. (n = 3). *, p < 0.05. (D–F) Type I collagen (D), fibronectin (E), and type V collagen (F) mRNA levels. mRNA expression levels are shown relative to the control value of 1 (untreated cells). Data are means ± S.D. (n = 3). *, p < 0.05; **, p < 0.01. Cont, untreated controls; Levo, levofloxacin; Cipro, ciprofloxacin. Treatment of mouse tendon cells with 100 µM levofloxacin or ciprofloxacin for 48 h results in reduced type I collagen and fibronectin and increased type V collagen protein and mRNA levels. (A–C) Type I collagen (A), fibronectin (B), and type V collagen (C) protein expression. β actin was used as the loading control. The band intensities were measured by densitometry and normalized to each β actin (loading control) intensity, and the intensity of the control sample band (untreated cells) was set to 1. Each value is shown relative to this control value. Data are means ± S.D. (n = 3). *, p < 0.05. (D–F) Type I collagen (D), fibronectin (E), and type V collagen (F) mRNA levels. mRNA expression levels are shown relative to the control value of 1 (untreated cells). Data are means ± S.D. (n = 3). *, p < 0.05; **, p < 0.01. Cont, untreated controls; Levo, levofloxacin; Cipro, ciprofloxacin. We further explored the functional role of FQs in the structural integrity of type I collagen in vitro. Immunofluorescence analysis revealed that treatment of tendon cells with FQs (100 µM levofloxacin and ciprofloxacin) resulted in significant inhibition of the assembly capacity of type I collagen (~ 64% inhibition by levofloxacin and ~ 75% inhibition by ciprofloxacin). Structurally, treatment with FQs resulted in a markedly sparser type I collagen fibril network compared to untreated controls (Fig. 4A). Furthermore, treatment of tendon cells FQs (again at 100 µM levofloxacin and ciprofloxacin) resulted in a significant reduction in hydroxyproline content, reflecting a reduction in total collagenous ECMs (p < 0.01; Fig. 4B). However, the extent of reduction in hydroxyproline content was much less (only ~ 21% with levofloxacin and ~ 27% with ciprofloxacin) compared to that observed in type I collagen assembly (Fig. 4A).Fig. 4Treatment of mouse tendon cells with FQs results in reduced type I collagen network and hydroxyproline content. (A) Left panels: Double immunofluorescence staining of the cells for type I collagen (assembly, in red) and with DAPI (4′,6-diamidino-2-phenylindole) nuclear counterstain (in blue) after 48 h of treatment with or without levofloxacin or ciprofloxacin. Scale bar = 100 µm. Right panel: Quantification of type I collagen positive areas. Data are means ± S.D. (n = 3). **, p < 0.01. (B) Hydroxyproline content of tendon cell cultures after exposure to 100 µM levofloxacin or ciprofloxacin for 5 days. Data are means ± S.D. (n = 3). **, p < 0.01. Cont, untreated controls; Levo, levofloxacin; Cipro, ciprofloxacin. Treatment of mouse tendon cells with FQs results in reduced type I collagen network and hydroxyproline content. (A) Left panels: Double immunofluorescence staining of the cells for type I collagen (assembly, in red) and with DAPI (4′,6-diamidino-2-phenylindole) nuclear counterstain (in blue) after 48 h of treatment with or without levofloxacin or ciprofloxacin. Scale bar = 100 µm. Right panel: Quantification of type I collagen positive areas. Data are means ± S.D. (n = 3). **, p < 0.01. (B) Hydroxyproline content of tendon cell cultures after exposure to 100 µM levofloxacin or ciprofloxacin for 5 days. Data are means ± S.D. (n = 3). **, p < 0.01. Cont, untreated controls; Levo, levofloxacin; Cipro, ciprofloxacin. The maximum concentration of levofloxacin in human soft tissues after a single intravenous dose of 500 mg is ~ 12 µM34. We therefore further investigated the type I collagen fibril network organization at lower FQ concentrations. Collagen assembly was significantly inhibited by FQs (~ 59% and ~ 65% inhibition at 10 µM levofloxacin and ciprofloxacin, and ~ 44% and ~ 52% inhibition at 1 µM (Suppl Fig. 1). Effect of FQ ciprofloxacin on collagen nanomechanical properties and integrins There is an emerging view that the mechanical properties of tendon ECM are crucial for adult tendon homeostasis and remodeling following injury35,36. Since lysyl oxidase (LOX) is a collagen cross-linking enzyme that catalyzes the conversion of lysine residues, and plays a central role in regulating tissue stiffness37, we explored whether FQs could alter the enzymatic activity of LOX in tendon cells in vitro. Treatment of tendon cells with ciprofloxacin slightly (~ 13%), but significantly (p < 0.05; Fig. 5) downregulated LOX enzymatic activity at 5 days of treatment. To further address how FQs affect the stiffness of formed collagen fibrils, the nanomechanical properties of collagen fibrils were investigated using atomic force microscopy (AFM). Treatment of tenocytes with ciprofloxacin significantly reduced collagen fibril elastic modulus (~ 67%) and diameter (~ 45%) in vitro (Fig. 6).Fig. 5Effect of FQ ciprofloxacin on LOX enzymatic activity in mouse tendon cells after up to 5 days of treatment. Cells were treated with 100 µM ciprofloxacin for various time periods followed by protein extraction and quantification of LOX activity using a fluorometric assay. LOX activity (unit) is measured as µg of LOX substrate converted per minute. Data are means ± S.D. (n = 3). *, p < 0.05. Cipro, ciprofloxacin.Fig. 6FQ ciprofloxacin induces reduction of collagen fibril elastic modulus and diameter in vitro by AFM in mouse tendon cells. (A) AFM images showing a map of topography (height; upper panels) and peak force error (lower panels) of collagen fibrils in mouse tendon cells cultured for 72 h with or without 100 µM ciprofloxacin. (B) Collagen fibril elastic modulus and (C) fibril diameter measured using AFM in tendon cells cultured for 72 h with or without 100 µM ciprofloxacin. Data are means ± S.D. (n = 4 in stiffness; n = 6 or 5 in diameter). Cipro, ciprofloxacin. Effect of FQ ciprofloxacin on LOX enzymatic activity in mouse tendon cells after up to 5 days of treatment. Cells were treated with 100 µM ciprofloxacin for various time periods followed by protein extraction and quantification of LOX activity using a fluorometric assay. LOX activity (unit) is measured as µg of LOX substrate converted per minute. Data are means ± S.D. (n = 3). *, p < 0.05. Cipro, ciprofloxacin. FQ ciprofloxacin induces reduction of collagen fibril elastic modulus and diameter in vitro by AFM in mouse tendon cells. (A) AFM images showing a map of topography (height; upper panels) and peak force error (lower panels) of collagen fibrils in mouse tendon cells cultured for 72 h with or without 100 µM ciprofloxacin. (B) Collagen fibril elastic modulus and (C) fibril diameter measured using AFM in tendon cells cultured for 72 h with or without 100 µM ciprofloxacin. Data are means ± S.D. (n = 4 in stiffness; n = 6 or 5 in diameter). Cipro, ciprofloxacin. Finally, we sought to investigate whether ciprofloxacin affects the expression of β1 integrin, the main ECM receptor, by fluorescence activated cell sorting (FACS) analysis, using an anti-β1 integrin monoclonal antibody (clone 9EG7) that recognizes an extracellular epitope of ligand-inducible active β1 integrin38. The mean fluorescence intensity exhibited a significant decrease 24 h after treatment with ciprofloxacin (~ 34%) compared to the control, indicating decreased expression of active β1 integrin (Fig. 7).Fig. 7Treatment of mouse tendon cells with 100 µM ciprofloxacin for 24 h results in reduced expression of active β1 integrin in the cells by FACS analysis. Analysis of mean fluorescent intensity in active β1-integrin. Data are means ± S.D. (n = 3). **, p < 0.01. Cipro, ciprofloxacin. Treatment of mouse tendon cells with 100 µM ciprofloxacin for 24 h results in reduced expression of active β1 integrin in the cells by FACS analysis. Analysis of mean fluorescent intensity in active β1-integrin. Data are means ± S.D. (n = 3). **, p < 0.01. Cipro, ciprofloxacin. Discussion Although a previous study has shown that FQ antibiotics can alter the biomechanical properties of adult tendons39, no framework exists for understanding the phenotypes relating to how tendon cell-produced ECM and related molecules change in response to these antibiotics. The present study on tendon cells in vitro provides evidence for the following propositions: (1) Carrier-mediated intracellular uptake of the FQ ciprofloxacin was demonstrated by mouse tendon cells in vitro; (2) FQ antibiotics significantly downregulate not only the production of the main component of tendon ECM, type I collagen, and its mRNA levels, but also its assembly capacity and hydroxyproline content, which are accompanied by significantly reduced fibronectin production; (3) treatment of tendon cells with ciprofloxacin significantly downregulates LOX enzymatic activity and collagen fibril stiffness and diameter in vitro; 4) tendon cells treated with ciprofloxacin show significantly decreased expression of active β1-integrin, the main ECM receptor. Our FQ uptake inhibition assays and transporter qRT-PCR analysis are consistent with the wider literature that has shown that the influx carrier OATP1A5 (slco1a5), a mouse homologue of human OATP1A2, could play a role in the intracellular accumulation of ciprofloxacin26,27, but we have now shown this in tendon cells for the first time. However, our findings also indicate that OATP1A5 does not account for all of the observed ciprofloxacin intracellular uptake by mouse tendon cells, suggesting that tendon cells could possess multiple transporters for FQ uptake. Indeed, differences in carrier-mediated transport cause variations in intracellular FQ accumulation among individual cell types and different FQs. A wider range of transporter screening analysis, including the use of efflux transporter inhibitors, would help identify further specific transporters in tendon cells. We also show that type I collagen fibril network was much more highly inhibited than hydroxyproline content after exposure to FQs (Fig. 4). This strongly suggests that we cannot attribute the reduction in the FQ-induced type I collagen network to reduced hydroxyproline production alone. Indeed, the extent of reduction in type I collagen network organization in tendon cells showed some differences between levofloxacin and ciprofloxacin, which could be due to differences in either cellular accumulation levels of each FQ or in FQ-mediated metal chelation. Furthermore, the production of type V collagen was increased following FQ treatment. We have recently demonstrated that there are at least two independent mechanisms of type I collagen assembly, fibronectin-mediated and type V collagen-mediated32,33. Since the diameter of type I collagen fibrils is inversely proportional to the type V/type I collagen ratio40,41, we hypothesize that treatment with FQs could affect the mechanical properties of collagen fibrils produced by adult tendon cells. Furthermore, the reduced type I collagen network organization, as seen in vitro at therapeutic FQ levels (Suppl Fig. 1), could be correlated with the increased risk of FQ-related tendon rupture. The present AFM analysis provides evidence that treatment of tenocytes with ciprofloxacin significantly reduced collagen fibril elastic modulus (~ 67%) and diameter (~ 45%) in vitro (Fig. 6). AFM provides information on local fibril size/topography and relative nanomechanical changes, while our immunofluorescent staining of type I collagen provides complementary lower-resolution evidence of altered type I collagen distribution and shows broader changes in type I collagen distribution/network patterning at the tissue level. Indeed, the fibrils measured in the present study by AFM are within the native ECM environment rather than isolated collagen fibrils. It would be interesting to investigate further the altered type I collagen fibrils using higher resolution equipment such as second harmonic generation (SHG) microscopy. An intrinsic characteristic of FQs is their propensity to bind metal cations to form chelates42, and as a consequence, FQ antibiotics have been shown to inhibit enzymes such as α-ketoglutarate-dependent dioxygenases that require iron as a cofactor in human embryonic kidney HEK293 cells43. One such enzyme, collagen prolyl-4-hydroxylase, plays a crucial role in the post-translational modification of collagen by catalyzing the post-translational hydroxylation of proline residues. However, there are several other metal-dependent processes such as lysine cross-linking by LOX with Cu2+ as a cofactor37; digestion of ECMs by matrix metallopeptidases with Zn2+ as a cofactor44; and adhesion of β1-integrin to the ECM, which requires Mg2+ and Ca2+ as cofactors45 that could possibly be affected by FQs. These facts are consistent with our finding that FQ antibiotics significantly reduce collagen hydroxyproline content and LOX enzymatic activity, and significantly decrease collagen fibril stiffness and diameter and active β1-integrin levels in tendon cells. Furthermore, other studies using rodent models have shown that oral administration of FQs (20–50 mg/kg for 3–4 weeks) results in a deterioration in the biomechanical properties of tendons39 and leads to degenerative changes in tenocytes46. Thus, we hypothesize that FQs influence the activity of collagen-modifying molecules and thereby alter the biomechanical properties of tendon tissue. Although iron chelation is suggested to be a primary mechanism of inhibition43, this is a neglected area of study that remains to be elucidated in tendon tissues. Since the primary mechanism of FQ-induced tendinopathy has not yet been established, it is difficult to address its pathology. There is an established notion that cells sense their location through specific interactions with the ECM, and that inappropriate cell-ECM interactions and environments induce cell death – termed “anoikis” in this context47,48. We have previously shown that fibronectin acts as an essential survival factor in hepatocytes, and that the matrix survival signals it mediates are transduced through the PI3K/BcL-xL-signaling axis following acute liver injury in vivo49. Here, our present findings revealed that treatment of tendon cells with FQs significantly reduced type I collagen network organization and collagen stiffness, which was accompanied by a significant reduction of both fibronectin production and active β1 integrin expression. Therefore, it is tempting to speculate that the reduction in fibronectin production and active β1 integrin expression lead to FQ-associated anoikis, which could be the pathological basis for a higher risk of tendinopathy. Clearly there is great demand for antibiotics due to the rise in antimicrobial resistance, and this is exacerbated by the dearth in the development of new antibiotics. The serious ADRs which have been reported with FQs have quite rightly led to a restriction in their use. However, FQs continue to be widely used with many patients suffering serious, and sometimes life-changing, ADRs. In this short paper, we present some novel findings which shed light on the potential mechanisms underlying FQ-associated tendon adverse effects. However, further work is needed in this area, including in FQAD, to understand the mechanisms of these ADRs and to develop intervention strategies that can be used to overcome the ADRs, develop better treatments and diagnostics, and thereby improve the benefit-risk ratio of FQs. Materials and methods Cell culture The present study used previously established adult mouse tendon cell lines, and no live animals were used in the current experiments50,51. Mouse tendon cell lines were established in a previous study from primary cell cultures of Achilles tendons from 10-to-12-week-old Scx(flox/flox)/ScxGFP/p53(-/-) and Scx(flox/flox)/ScxGFP/p21(-/-) mice50. That mouse study was approved by the Institutional Animal Care and Use Committee of the Cleveland Clinic, Ohio. Briefly, Achilles tendons were harvested under sterile conditions, cut into small pieces, and digested in Dulbecco’s modified Eagle’s medium (DMEM) containing collagenase and trypsin, and the primary tendon cell cultures were established from pooled Achilles tendon cells obtained from multiple mice of each genotype because the cell yield from individual mice was insufficient to establish stable cultures. Multiple independent immortalized clones were generated from each genotype, and selected clones were used for the present study. Comparable phenotypes were confirmed in additional clones. Mouse tendon cell lines with passage number > 15 were used for the present study. Cells were maintained in DMEM supplemented with 10% FBS and 1% non-essential amino acids. All FQ-exposure experiments were performed using culture medium containing 5% dialyzed FBS. In studies performed over 2 or more days, cultures were re-dosed daily with FQs. Reagents and antibodies FQ antiboitics were purchased from Sigma. [3H]-Ciprofloxacin (0.05 mCi/ml; specific activity = 470 Ci/mmol) was from Moravek Inc. The following antibodies were used: rabbit polyclonal antibody (pAb) against mouse type I collagen (Chemicon; this antibody shows less than 0.1% reactivity with mouse collagen types II and IV in addition to 1.0% reactivity with mouse collagen type III); rabbit pAb against mouse fibronectin (Chemicon; this antibody has cross-reactivity to bovine fibronectin, and shows less than 0.1% reactivity with mouse laminin and collagen types I, III, and IV by radioimmunoassay); rabbit pAb against the C-telopeptide of the α1 chain of type I collagen (LF68; kindly provided by Dr. Larry Fisher, NIH, USA); goat pAb against human type V collagen (Thermo Fisher); and rat mAb against mouse integrin β1 (clone 9EG7; BD PharminGen)38. Alexa Fluor 647-conjugated goat anti-rat IgG and Alexa Fluor 568-conjugated goat anti-rabbit IgG were from Molecular Probes. MTS reagent was from Promega, the hydroxyproline assay kit was from Sigma, and the lysyl oxidase activity assay kit was from Abcam. FQ uptake assay The uptake assay was conducted as previously described25. Cells were seeded at 3 × 105 cells/well in 6-well plates and cultured for 12 h in growth medium. Drug cocktail was made up in transport buffer consisting of Hanks balanced salt solution (HBSS) (pH7.4) with BSA. Radiolabeled ciprofloxacin (0.5 µCi/ml) and cold ciprofloxacin were added to the transport buffer to achieve a final drug concentration of 10 µM. Radiolabelled and cold ciprofloxacin were omitted from the negative control. The cocktail was warmed at 37 °C for 15 min prior to starting the assay. The medium was removed from the wells followed by washing with 37 °C HBSS. To initiate the reaction, HBSS was removed and replaced with 1 ml of drug cocktail and incubation carried out for up to 60 min (time course assay) or for 5 min (temperature and inhibitor assays) at 37 °C. To stop uptake, 1 ml ice-cold HBSS was added and the cells were washed three times, after which 0.5 ml sodium dodecyl sulphate (5%) was added to obtain lysate. The lysate was then transferred to a scintillation tube and scintillation cocktail added. Radioactivity was determined using a scintillation counter with a protocol specific for [3H] (1500 Tri-Carb LS Counter; Packard Meriden). The results were converted to picomoles per million cells. MTS assay To assess cell viability, tetrazolium dye (MTS) colorimetric assay was conducted according to the manufacturer’s instructions. Briefly, cells were seeded on a 96-well plate at a density of 1 × 104 per well and incubated for 24 h in 100 µl culture medium. The medium was then removed and 100 µl of fresh medium containing test compound added. The plate was further incubated for 24 h, MTS reagent (20 µl) was added to each well, and the cells were incubated for a further 2 h. The absorbance was then measured at 490 nm using a 96-well plate reader. A negative control was set up consisting of cells in cultured medium containing vehicle. Cell viability was expressed as a percentage of that of the negative control. Hydroxyproline assay Hydroxyproline content was measured using colorimetric analysis, and the assay was conducted according to the manufacturer’s instructions. Briefly, tendon cells were treated with ascorbic acid (50 µg/ml) to stimulate collagen production and incubated with or without FQs. An amount of cells corresponding to 10 mg total protein The cells were homogenized, 100 µl of concentrated hydrochloric acid (HCl, ~ 12 M) was added, and the protein was hydrolyzed at 120 °C for 3 h. The samples (10 µl of supernatant) were transferred to a 96-well plate. Following the addition of 100 µl Chloramine-T/oxidation buffer mixture to each well, p-dimethylaminobenzaldehyde (DMAB) reagent (DMAB concentrate with perchloric acid/isopropanol; 100 µl) was added. Plates were then incubated for 90 min at 60 °C and the absorbance was measured at 560 nm. Standards were set up at 0.2–1 µg/well to generate a standard curve. LOX activity assay LOX activity was measured using fluorometric analysis in which LOX substrate releases hydrogen peroxide upon oxidation and the hydrogen peroxide is detected via horseradish peroxidase (HRP)-coupled fluorescent reactions. The assay was conducted according to the manufacturer’s instructions. Briefly, tendon cells were treated with ascorbic acid (50 µg/ml) to stimulate collagen production and incubated with or without FQs. The cells were then lysed in cold PBS and sonicated. Following centrifugation, protein levels were determined using the BCA protein assay (ThermoFisher). The samples were then diluted in cold PBS containing 0.1% BSA, and transferred to a 96-well plate. Following the addition of 50 µl LOX reaction mix consisting of 250 × HRP substrate, 50 U/ml HRP stock and assay buffer containing the LOX substrate, the reaction mixture was incubated at 37 °C for 30 min in the dark. The fluorescence signal was detected at an excitation wavelength at 540 nm and an emission wavelength at 590 nm using a Varioskan Flash plate reader. A unit of LOX activity was defined as 1 µg of LOX substrate converted per minute. Atomic force microscopy The nanomechanical properties of collagen fibrils in tendon cell culture were investigated with atomic force microscopy (AFM: NanoScope VIII MultiMode AFM, Bruker Nano Inc., Santa Barbara, CA). Three individual cell-culture samples were treated with FQ ciprofloxacin for 72 h, and another three samples served as controls. The AFM was equipped with a J-scanner, operated with the Peakforce Quantitative Nanomechanical Mapping (PFQNM) modality. The circular glass cover slips were adhered to metal support stubs, following which the samples were imaged at ambient conditions using the RTESPA-150 Bruker probe, which was made of a silicon nitride tip and had a nominal tip radius of 8 nm. The cantilever of the probe had a spring constant of 5 N/m. The PFQNM method was calibrated using a reference polymer (PS1, Vishay Measurements Group UK) with a known elastic modulus (2.7 ± 0.1 GPa). The spring constant and deflection sensitivity were calibrated using the reference sample, and the same AFM probe was used for imaging every sample. The elastic modulus was determined by fitting the data with the Derjaguin–Muller–Toporov (DMT) model to extract the elastic modulus, as described previously33. Images measuring 5 × 5 μm were collected, and the elastic modulus was determined using Bruker NanoScope software, version 1.5. Each image had a resolution of 256 indents/line. The elastic modulus and collagen fibril diameter were determined in each sample to calculate the mean. Immunofluorescence Immunofluorescent studies were performed as described elsewhere38,52, except that the Triton X-100 treatment for cell permeabilization was omitted to permit the detection of type I collagen in the ECM. Briefly, tendon cells were stimulated with 50 µg/ml ascorbic acid and treated with or without levofloxacin or ciprofloxacin (1–100 µM). Cells were then fixed in 4% paraformaldehyde in PBS for 10 min, followed by washing with PBS. The cells were incubated with 3% BSA for 30 min at room temperature, and then incubated with pAb against mouse type I collagen at 4 °C overnight followed by Alexa Fluor 568 goat anti-rabbit IgG for 45 min at room temperature. Cells were then washed and mounted on a Vectashield (Vector Labs) with 4,6-diamidino-2-phenylindole (DAPI). In type I collagen networks, images were all captured with the same gain, offset, magnitude, and exposure time. For quantification of type I collagen network-positive areas, three different cell images were randomly selected and their intensities quantified using ImageJ software (version 1.48; National Institutes of Health)49. Real-time PCR Real-time PCR was performed as described elsewhere53. Briefly, total RNA was isolated from tendon cells using TRIzol reagent (Invitrogen). Total RNA (0.5 µg) that had been treated with DNase I (Ambion) was reverse transcribed using the SuperScript™ III First-Strand Synthesis System for Reverse Transcriptase–PCR (Invitrogen) with random primers according to the supplier’s protocol. Then synthesized cDNA was amplified using the SYBR Green PCR Master Mix (Applied Biosystems) and 7500 Real-Time PCR System (Applied Biosystems). The following primers were used: collagen type I (Col1a1) forward, 5’-TTTGTGGACCTCCGGCTC-3’; collagen type I (Col1a1) reverse, 5’-AAGCAGAGCACTCGCCCT-3’; collagen type V (Col5a1) forward, 5’-AGGACCACACAGGGAAGC-3’; collagen type V (Col5a1) reverse, 5’-CTTGTAGACACTGAGAGCAATTCG-3’; fibronectin forward, 5’-GGCTCCAGATCCATCCAACAC-3’; fibronectin reverse, 5’-GACAGCCACTTTCACAGACAG-3’; 18S rRNA forward, 5’-GGCGACGACCCATTCG-3’; and 18S rRNA reverse, 5’-ACCCGTGGTCACCATGGTA-3’. All samples were analyzed at least in triplicate. After the reactions, the specificity of amplification in each sample was confirmed by dissociation analysis, showing that each sample gave a single melting peak. mRNA levels were normalized to the level of 18S rRNA. Western blot analysis Western blot analysis was performed as described elsewhere53,54, except for the addition of a cell lysis step using RIPA buffer. Briefly, tendon cells were treated with or without 100 µM levofloxacin or ciprofloxacin for 48 h. Cells were lysed on ice in RIPA buffer containing 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 150 mM NaCl, 10 mM EDTA, 20 mM, sodium fluoride, 2 mM PMSF, 5 µg/ml leupeptin, 0.4 mM pefabloc SC, and 50 mM Tris–HCl, pH 8.2. The same amounts of protein (20 µg) were used for analyses, as determined using a BCA protein assay (ThermoFisher). The proteins were run on SDS–polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions, and transferred onto an Immobilon-FL polyvinylidene fluoride (PVDF) membrane (Millipore Corp.) with Trans-Blot cell (Bio-Rad Lab.). The membrane was incubated Tris-buffered saline (TBS) containing 1% BSA and 0.05% Tween 20, and then probed with primary antibodies, and IRDye 800CW- or IRDye 680-conjugated secondary antibodies (LI-COR Biosciences). Immunoreactive bands were detected using the Odyssey IR Imaging System (LI-COR Biosciences). The band intensities were measured by densitometry using Image Studio software (version 3.0; LI-COR Biosciences). FACS analysis FACS analysis was performed as described elsewhere38,55. Briefly, tendon cells on a 6-well plate were treated with or without 100 µM ciprofloxacin for 24 h. The cells were detached using EDTA/PBS. Cells were then incubated with rat mAb against active β1 integrin (9EG7) for 30 min at 4 °C. Following washing with PBS containing 1% BSA, the cells were incubated with Alexa Fluor-647-conjugated anti-rat IgG. The immunoreactivity of the cells was measured using an Attune NxT acoustic focusing cytometer (Life Technologies). The FACS gating strategy was: (1) to exclude debris/dead cells and select single cells checking forward and side scatter areas; (2) to define target phenotype (specific fluorescent marker) by comparing between stained and unstained cells. Data presentation and statistical analysis All experiments were performed at least in triplicate. For the Western, immunofluorescence and AFM data, representative gels, photomicrographs or AFM images are shown alongside the analytical results. Results are presented as means ± standard deviation (S.D.). Differences between groups were analyzed using the two-sided Student’s t-test on raw data. In cases where more than two groups were compared, one-way ANOVA and Dunnett’s post-hoc test were used. A p value of < 0.05 was considered significant. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1